Last reviewed · How we verify
HDM1002 and rifampicin — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
HDM1002 and rifampicin (HDM1002 and rifampicin) — Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HDM1002 and rifampicin TARGET | HDM1002 and rifampicin | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HDM1002 and rifampicin CI watch — RSS
- HDM1002 and rifampicin CI watch — Atom
- HDM1002 and rifampicin CI watch — JSON
- HDM1002 and rifampicin alone — RSS
Cite this brief
Drug Landscape (2026). HDM1002 and rifampicin — Competitive Intelligence Brief. https://druglandscape.com/ci/hdm1002-and-rifampicin. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab